FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

14:00 EST 13 Feb 2020 | Drugs.com

THURSDAY, Feb. 13, 2020 -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk of cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S....

Original Article: FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk

More From BioPortfolio on "FDA Requests Market Withdrawal of Diet Drug Belviq Due to Cancer Risk"